According to a recent LinkedIn post from Quell Therapeutics, the company is participating in the EULAR 2026 Congress in London. The post highlights a presentation of additional pre-clinical data for QEL-005, a novel targeted Treg cell therapy candidate, and an update on the CHILL clinical study in refractory rheumatoid arthritis and systemic sclerosis.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post indicates that CHILL is a multinational trial recruiting patients in the U.K., Germany, and Spain, with enrollment already underway at leading U.K. clinical centers. Early clinical findings are suggested to be expected in Q1 2027, a timeline that may be relevant for investors monitoring value inflection points in Quell’s autoimmune pipeline.
From an investor perspective, the focus on pre-clinical data for QEL-005 and the expansion of the CHILL study underscore Quell’s commitment to Treg cell therapies in difficult-to-treat autoimmune indications. If forthcoming clinical data validate the pre-clinical profile, the program could enhance the company’s positioning in the competitive autoimmune and cell-therapy landscape and potentially support future partnership or financing opportunities.